Related Experiment Videos
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
H Seggewiss1, L Faber, P Ziemssen
1Kardiologische Klinik, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Georgstr. 11, 32545 Bad Oeynhausen, Germany. seggewiss.hubert@t-online.de
Cardiology in Review
|February 24, 2001
Summary
Percutaneous transluminal septal myocardial ablation offers a new treatment for hypertrophic obstructive cardiomyopathy. This procedure widens the left ventricular outflow tract, reducing gradients and improving patient outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Surgical myectomy was the primary treatment for drug-refractory hypertrophic obstructive cardiomyopathy until the early 1990s.
- Newer therapeutic options have emerged, including DDD-pacemaker implantation and percutaneous transluminal septal myocardial ablation.
Purpose of the Study:
- To review the latest outcomes of percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
- To highlight the effectiveness of alcohol-induced septal branch occlusion in managing this condition.
Main Methods:
- Percutaneous transluminal septal myocardial ablation involves inducing a localized myocardial infarction via alcohol injection into a septal branch.
- This procedure aims to widen the left ventricular outflow tract and reduce the obstructive gradient.
Main Results:
- The procedure leads to a circumscribed therapeutic myocardial infarction, widening the left ventricular outflow tract.
- Follow-up studies demonstrate significant clinical improvement and sustained gradient reduction due to left ventricular remodeling.
Conclusions:
- Percutaneous transluminal septal myocardial ablation is a viable and effective alternative to surgical myectomy for select patients.
- The technique offers impressive clinical benefits and favorable long-term outcomes in managing hypertrophic obstructive cardiomyopathy.